TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00536744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acoustical pulse energy (extracorporeal shockwave)
Description: Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Non-energized (inactive - Sham) application + standard of care
Study: NCT00417326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5046Na
Description: twenty four hour infusion at 0 mg/kg/hr for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5046Na
Description: twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
Study: NCT00595088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC-819/PEI
Description: Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
Study: NCT03391362

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
Study: NCT04089787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Shortened antibiotic treatment of 5 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Antibiotic treatment of 7 days or longer at the discretion of the treating physician
Study: NCT03435211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00006
Description: Noninvasive pulse oximeter sensor
Study: NCT02759419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adempas (Riociguat, BAY63-2521)
Description: 0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
Study: NCT04097301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
Description: Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
Study: NCT04447664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclouded telespirometry system
Description: Components of the system: Portable digital ultrasonic spirometer (Uscom SpiroSonic MOBILE), android mobile application, clinical web cloud application
Study: NCT00840151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
Study: NCT04020809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Anti-PD-L1 monoclonal antibody
Study: NCT02129543

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
Study: NCT04222309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopically harvested omental free flap
Description: Laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
Study: NCT04536909

Intervention type: OTHER
Intervention: Non-surgical
Description: We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.

Intervention type: PROCEDURE
Intervention: Surgical
Description: Surgery for correction of kyphotic- or scoliotic deformity.
Study: NCT04501523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, q3w, for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 600-750 mg/m2 PO Bid，continuous, for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 600-750 mg/m2 PO Bid，continuous, for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 600-750 mg/m2 PO Bid，continuous, for 1 year
Study: NCT03880097

Intervention type: PROCEDURE
Intervention: Research Biopsy
Description: The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes.
Study: NCT01710982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TZP-101

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04294134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MIO-CPP
Description: Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) Studies have revealed that CPP caregivers' outcomes include decreased depression, PTSD and other symptoms, increased empathy towards children and an increase in the quality of parent-child interactions. CPP focuses on working with families offering weekly sessions for nine-12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIO-CPP-CRS
Description: Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) CPP focuses on working with families offering weekly sessions for nine-12 months.~Certified Recovery Specialists (CRS) provide peer support services are an evidence-based...model of care which consists of a qualified peer support provider who assists individuals with their recovery from mental illness and substance use disorders.
Study: NCT04046497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: artificial intelligence (AI) smartphone app to provide support for medication adherence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care provided by CSC clinic
Study: NCT02142699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heme arginate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heme arginate
Study: NCT02891447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intraperitoneally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Undergo HIPEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given intraperitoneally
Study: NCT01375829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT02991768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entocort
Description: A corticosteroid that decreases levels of inflammatory cytokines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo is matched to the study drug.
Study: NCT03604783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-1287
Description: TP-1287 by oral administration
Study: NCT01416220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l.
Study: NCT00633724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
Study: NCT04103060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib 0.37% gel
Description: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel applied topically twice daily for 6 weeks
Study: NCT00541060

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: mutation
Description: a mutation of a gene coding

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: mutation
Description: a mutation of a gene coding
Study: NCT01435330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVS857

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04178044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB223,7mg/kg
Description: Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB223,21mg/kg
Description: Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB223,63mg/kg
Description: Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB223,119mg/kg
Description: Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB223,140mg/kg
Description: Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
Study: NCT02032277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Veliparib
Description: Veliparib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Veliparib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Veliparib
Study: NCT01635920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens
Description: Silicone hydrogel contact lens
Study: NCT04644562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector Spinae plane block
Description: Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
Study: NCT01556477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine + lenalidomide
Description: Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks.
Study: NCT04217733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxyifylline
Description: Pentoxyifylline two times daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebeverine
Description: Mebeverine 3 times for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethosuximide
Description: ethosuximide 3 times for 3 months
Study: NCT02436785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Listening to relaxing music on a CD player for approximately an hour.
Study: NCT00588185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Description: Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
Study: NCT03187340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education and relaxation 1
Description: Sleep hygiene and relaxation training; Sleep education and relaxation 1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep education and relaxation 2
Description: Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
Study: NCT01534377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents
Description: Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
Study: NCT02704663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transumbilical removal of specimen via laparoscopy
Description: Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral transabdominal removal of specimen via laparoscopy
Description: Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
Study: NCT03017534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manual Therapy
Description: Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
Study: NCT01128816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Servo Ventilation
Description: BiPAP autoSV ADVANCED device worn nightly during sleep
Study: NCT04415723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supportive care management programme
Description: nurse-led management programme
Study: NCT01531010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation protocol delivered by the SLE5000 ventilator
Description: In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation protocol delivered by the SLE5000 ventilator
Description: In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits.